Daily News

In Response To Drug Makers, CMS Rethinks Common Billing Codes For Biosimilars

July 14, 2017
In response to drug makers, CMS is considering undoing the policy of putting biosimilars that reference the same brand biologic in common billing codes, even though congressional Medicare advisers recommend that the agency use the policy more aggressively by grouping pay of both brands and biosimilars. The Obama administration instituted the policy to get biosimilars makers to compete on price, and CMS expects to soon group payment for the first time for two biosimilars. The Physician Fee Schedule rule that...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting as congressional Republicans take another run at repealing Obamacare.